25 July 2018 - Just Published: PET and fMRI imaging on NLX-112 and NLX-101

An innovative brain imaging study combined Positron Emission Tomography (PET) and functional Magnetic Resonance Imaging (fMRI) to characterize the labeling and functional connectivity of NLX-112 and NLX-101. Both compounds are highly selective for serotonin 5-HT1A receptors but exhibit preferential interaction (or 'biased agonism') at specific receptor sub-populations. NLX-112 is being developed for treatment of dyskinesia in Parkinson's disease, whereas NLX-101 is a candidate for treatment of Rett syndrome. The imaging study was carried out at the Lyon Neuroscience Research Center (France) by the team of Prof. Luc Zimmer, with whom Neurolixis has a long-standing collaboration.


In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET/MR imaging.

Vidal B, Fieux S, Redouté J, Villien M, Bonnefoi F, Le Bars D, Newman-Tancredi A, Costes N, Zimmer L.
Neuropsychopharmacology. 2018 Jul 6. doi: 10.1038/s41386-018-0145-2. PMID: 30030540

28 June 2018 - Neurolixis Appoints Dr. Ronan Depoortère, PhD, as Director of Pharmacology

Neurolixis Inc. offers a warm welcome to Ronan Depoortere, PhD, as Director of Pharmacoogy.
Dr. Depoortere has gained extensive experience of neuropharmacology in several large and medium-sized pharmaceutical companies where he managed in vivo behavioral studies on CNS drug candidates. His expertise will be valuable as Neurolixis moves forward with development of its drug pipeline targeting Parkinson's disease and Rett syndrome and in characterizing development candidates from the drug discovery program.

See more information concerning Neurolixis' management team here.